MK0429 Study in Prostate Cancer Patients With Metastatic Bone Disease (0429-011)

A Phase I, Randomized, Multicenter, Double-Blind Study of MK0429 in the Treatment of Men With Hormone Refractory Prostate Cancer and Metastatic Bone Disease

This two part study will evaluate the safety and tolerability of MK0429 in addition to assessing it's pharmacokinetic profile and pharmacodynamic response.

Inclusion Criteria:

• Eligible patients must have:

  • Prostate cancer
  • Bone metastases without symptoms
  • Lack of response to hormone therapy as evidenced by a rising PSA or clinical progression

Exclusion Criteria:

• Prostate cancer-related bone pain
• Previously received bisphosphonate therapy (e.g. zoledronate)
• Received any investigational treatment within the last 30 days